July 24, 2014 4:05 AM ET

Pharmaceuticals

Company Overview of Sigma-Tau Pharmaceuticals, Inc.

Company Overview

Sigma-Tau Pharmaceuticals, Inc., a research-based pharmaceutical company, focuses on the discovery, development, and commercialization of molecules and therapies to help improve the lives of people who suffer from rare diseases. The company offers prescription pharmaceuticals for rare diseases that include tablets, oral solutions, sugar-free oral solutions, and injections; and capsules. It also offers nonprescription medicines and dietary supplements that help to support the normal functions of body. In addition, the company provides third party manufacturing services for customers in the United States, Canada, Mexico, Brazil, Europe, the Middle East, and Africa. Its products cover areas, su...

9841 Washingtonian Boulevard

Suite 500

Gaithersburg, MD 20878

United States

Founded in 1980

Phone:

301-948-1041

Fax:

301-948-1862

Key Executives for Sigma-Tau Pharmaceuticals, Inc.

Chief Executive Officer
Senior Director of Finance
Chief Executive Officer of Sigma-Tau Group
Vice President of Medical Affairs
Vice President of Clinical Affairs
Age: 58
Compensation as of Fiscal Year 2014.

Sigma-Tau Pharmaceuticals, Inc. Key Developments

Sigma-Tau Pharmaceuticals, Inc. Announces Availability of CYSTARAN(TM) 0.44%

Sigma-Tau Pharmaceuticals, Inc. announced the availability of CYSTARAN(TM) (cysteamine ophthalmic solution) 0.44%, the first and only FDA-approved therapy for the treatment of corneal cystine crystal accumulation in patients with cystinosis. Sigma-Tau developed CYSTARAN in partnership with the National Institutes of Health (NIH) and in cooperation with the Cystinosis Foundation, the Cystinosis Research Foundation, and the Cystinosis Research Network. The U.S. Food and Drug Administration (FDA) approved CYSTARAN in October 2012, and the product has also been granted Orphan Drug status. CYSTARAN is available as a sterile ophthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride equivalent to 4.4 mg/mL of cysteamine (0.44%).

Sigma-Tau Pharmaceuticals, Inc. Promotes Dave Lemus to Chief Executive Officer

Sigma-Tau Pharmaceuticals, Inc. announced that Dave Lemus has been promoted to the newly created position of Chief Executive Officer, effective immediately. Mr. Lemus had served as Chief Operating Officer of the Company since March 2012, and joined the Company as Vice President of Finance in July 2011. Prior to joining Sigma-Tau Pharmaceuticals in 2011, Mr. Lemus was Executive Vice President and Chief Financial Officer of MorphoSys AG, where he launched Germany's first-ever biotechnology IPO in 1999. Mr. Lemus presently serves as Board Chairman of Proteros Gmbh in Munich, Germany, and as a Non-Executive Board Member of Toronto, Canada-based Axela Inc.

Sigma-Tau Pharmaceuticals, Inc. Announces U.S. Launch of VSL#3(R) JUNIOR

Sigma-Tau Pharmaceuticals, Inc. announced the U.S. launch of VSL#3(R) JUNIOR, a once-a-day, high-potency probiotic medical food for the dietary management of children who suffer from irritable bowel syndrome (IBS) and ulcerative colitis (UC). Unlike other marketed probiotics, VSL#3(R) JUNIOR is presently the only probiotic sold as a medical food for IBS and UC. Refrigerated VSL#3(R) JUNIOR contains 8 proprietary strains of 225 billion live bacteria, making it approximately 50 times more potent than the average probiotic. VSL#3(R) JUNIOR is natural and comes in a child-friendly watermelon flavor. It can be mixed into cold drinks, such as water and juice, or foods. Natural, VSL#3(R) JUNIOR is also gluten free, Kosher and Halal certified. Each box contains 30 of the watermelon flavored packets. VSL#3(R) JUNIOR is available nationwide, behind the counter, at participating pharmacies. As with all medical foods, the product must be used under medical supervision. In addition to VSL#3(R) JUNIOR, Sigma-Tau distributes three other formulations for adults: VSL#3(R) DS prescription-only medical food packets, containing 900 billion bacteria; VSL#3(R) packets, containing 450 billion bacteria, and; VSL#3(R) capsules, containing 112.5 billion bacteria.

Similar Private Companies By Industry

Company Name Region
Troy Manufacturing Inc. United States
ProlX Pharmaceuticals Corporation United States
PD Pharmatech United States
Desert West Marketing Inc United States
AvMax, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sigma-Tau Pharmaceuticals, Inc., please visit www.sigmatau.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.